Concept Life Sciences has a strong background in neuroscience and extensive academic links to leading research groups in the field. We help you to understand your MOA and to investigate your test compounds. We share expertise to help you understand your drug candidates, gathering robust data to drive confident decision making throughout your CNS drug discovery process.
We offer a consultative approach and a suite of customizable assays for investigating CNS (central nervous system) test compounds, including specialist histology readouts as well as ADME services and ensuring a comprehensive, tailored CNS program. We gather robust data to drive confident decision-making throughout your CNS drug discovery and development pipeline.
World-leading experts in the research of multiple sclerosis
We have world-leading experts in the research of multiple sclerosis (MS), a disease that requires understanding of immunology, inflammation and neuroscience. We can provide end-to-end support for MS drug discovery through in vitro OPC (Oligodendrocyte Precursor Cells) assays and our ex vivo slice model, a powerful screening and translational tool as well as lead compound assessment in our in vivo EAE, cuprizone and LPS MS models.
Our experienced Neuroscience team offer specialist discovery services to clients looking to develop novel therapies for a range of neurodegenerative conditions. We can tailor and develop neuroprotective screening assays to discover the mechanism of action of your drug candidate, with customized assays targeting neurons themselves and/or the supportive glial cells in isolation or co-culture.
We are developing a range of neurotoxicity services, including developmental neurotoxicity assays (DNT), using our pluripotent stem cell and primary CNS cell-based assay platforms that can support Pharma and non-Pharma clients in their regulatory and safety requirements.
Our suite of neuroscience services can be specifically tailored to your project:
- Primary CNS cell-based assays
- Ex vivo brain slice assays
- Human iPSC CNS disease models
- RNA and protein-based multiplex histology services
- Brain penetrant and receptor occupancy services
- Neurotoxicity assays